B.C. Patient Denied Funding for Cancer Treatment Due to Loophole

“They removed the lower right lobe of my lung and then surveillance from there,” Coleman said regarding his initial carcinoid tumour diagnosis, which was monitored for five years before the cancer returned.

Coleman is now fighting for public health coverage of peptide receptor radionuclide therapy, or PRRT, a targeted radiopharmaceutical treatment approved by his oncology team and the Liver Tumour Board. The report outlines how the British Columbia case faces funding denials because his primary neuroendocrine tumour originated in his lung rather than the gastrointestinal tract.

Key Clinical Takeaways:
• Coleman’s neuroendocrine tumours progressed on lanreotide therapy after initial surgeries for lung and liver tumours.
• A specialized PET scan confirmed his tumours possess the specific receptors required for peptide receptor radionuclide therapy (PRRT).
• British Columbia’s public funding criteria cover PRRT in certain cases involving gastrointestinal-origin neuroendocrine tumours, prompting an immediate administrative denial for his lung primary case.

The Pathological Progression From Lung to Liver

Coleman’s medical history spans multiple surgical interventions across several years. Following the initial five-year monitoring period after his lung-lobe surgery, doctors diagnosed a six-inch tumour in the right side of his liver in 2020. That December, surgeons performed a liver resection. Two years later, physicians discovered a new tumour in his right lung, prompting a middle right lobe removal in Vancouver.

Subsequent scans revealed three distinct tumours developing on the left side of his liver. Medical teams treated the largest mass with radiation and a smaller tumour with ablation. When a third lesion emerged, doctors ruled out further localized procedures due to concerns about damaging his liver. Clinicians then initiated monthly lanreotide injections to control his neuroendocrine tumours.

The treatment worked for more than a year. However, comparative imaging between February and July scans demonstrated progression, signaling the need for an alternative therapeutic strategy.

Tumour Board Approves Targeted Radiopharmaceutical Therapy for Coleman

Following disease progression on lanreotide, Coleman’s medical team evaluated him for peptide receptor radionuclide therapy. A specialized PET scan assessed whether his tumours had the receptors necessary for the targeted radiopharmaceutical approach, with encouraging results. Both his oncology team and the Liver Tumour Board approved PRRT as his next best option.

Public funding guidelines in British Columbia restrict coverage for the therapy based on the anatomical origin of the primary malignancy. B.C.’s framework covers PRRT in certain cases where a neuroendocrine tumour originates in the gastrointestinal tract. Because Coleman’s primary tumour developed in his lung, the funding request met an immediate administrative denial.

Janna Coleman, the patient’s wife, attempted to secure coverage through BC Cancer’s Compassionate Access Program, designed for exceptional cases outside standard funding criteria. According to Janna, that application was rejected within hours. Jennifer Marchand, CEO of the Canadian Neuroendocrine Tumour Society, noted that access for cases outside standard criteria varies by province, relying on individual rules and exceptional case requests.

Financial Realities and the Search for Advocacy

With public funding blocked, the Colemans explored alternative therapies, including oral drugs, though they maintain that PRRT remains their favoured next option. Paying privately for the multi-infusion radiopharmaceutical treatment could potentially cost between $150,000 and $200,000, creating substantial financial and logistical hurdles away from home.

BC Cancer officials noted during the post-election interregnum period that government operations remain in temporary caretaker mode, limiting communications to critical health and public safety information while care teams work directly with the family to explore options. For now, Coleman and his family continue to seek someone to reconsider the case and examine the medical evidence beyond the funding checkbox.

“We need somebody to go around the funding ‘no’ and advocate for the ‘yes.’ Because apparently there is a clinical ‘yes’ through the exceptional pathway. It needs to be reviewed, and nobody’s done it.”

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.